The Biosafety Bill, which the biotech industry is most worried about, has made new progress.

On December 7, the shoe finally dropped: the relevant provisions of the Biosafety Bill did not appear in the final negotiation text of the 2025 National Defense Authorization Act ("NDAA") after consultation by members of the Senate Armed Services Committee.

This shows that the attempt to include the Biosafety Bill in the 2025 NDAA has failed, and it will not pose an obstacle to the overseas expansion of companies such as BGI in the short term.

This is the case in the short term, and it is likely to be the case in the long term. In the eyes of the market, this is not the end, and there is still a possibility of being mentioned again in the future. This is the case in theory, but in fact, the "abortion" of the Biosafety Bill reflects a fact: the global biotech industry is a community and it is difficult to "decouple".

After the Biosafety Bill appeared, there was a lot of opposition, and even reports circulated overseas that it would become more moderate. The fact that it was finally "aborted" now shows that American politicians have actually returned to rationality and realized the above problems.

A more positive signal is that some politicians who oppose the biosafety bill will hold important positions in the next government. For example, Rand Paul, who cast the only opposing vote at the Senate Homeland Security and Governmental Affairs Committee hearing in March this year, was successfully elected as the new chairman of the Senate Homeland Security Affairs Committee.

This also means that the probability of irrational policies such as the biosafety bill being mentioned is actually getting lower and lower. This should be good news for the domestic biotechnology industry.

https://mp.weixin.qq.com/